BioTech / Biotech / Pharmaceuticals / Pharmaceutical / Vaccine / Drug / Drugs / Vaccines / Medicine / Therapeutics / RNAi / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Accelerator / aflibercept / allergy / Alnylam Pharma ceuticals / amazon / Amicus Therapeutics / apple / Approval / Biogen / cancer / clinical trials / cost / CVS / CVS Caremark / CVS Health / drug price / EpiPen / Express Scripts / Eylea / Fabry Disease / fasinumab / FDA / FDA approval / Gene Therapy / generic / google / guidance / hereditary transthyretin amyloidosis / HIV / ICER / Institute for Clinical Economic Review / interference / Kaiser Health News / Life Sciences / Macular Degeneration / Magnolia Neurosciences / Microsoft / migalastat / National Institute for Health and Care Excellence / nusinersen / Oncology / opidoids / Orchard Therapeutics / Prices / Pricing / rejection / RNA interfernece / RNAi medicine / Safety / Spinraza / Teva Pharmaceutical / therapeies / Trump administration / VC / Venture Capital / ViiV Healthcare

Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More

Posted on: Aug 17, 2018   |   Posted by: Biotech Mag

Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More

We'll start the roundup this week with two drug approvals that came late last Friday. Both were landmarks for the companies receiving the nod, Alnylam Pharmaceuticals and...

Continue reading ...